Human plasma kallikrein inhibitors

Patent metadata

Field	Value
Publication number	US-11708332-B2
Application number	US-202117526377-A
Country	US
Kind code	B2
Filing date	Nov 15, 2021
Priority date	Mar 7, 2014
Publication date	Jul 25, 2023
Grant date	Jul 25, 2023

Abstract

Disclosed are compounds of formula Ias described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

First claim

What is claimed is:

1. A compound having the structure of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

3. The compound of claim 1 , wherein the pharmaceutically acceptable salt is a bis(hydrochloride) salt.

4. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

6. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable salt is a bis(hydrochloride) salt.

7. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is formulated for parenteral administration.

8. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is formulated for oral administration.

9. A method of treating a disease or condition characterized by unwanted plasma kallikrein activity, comprising administering to a subject in need thereof a pharmaceutical composition of claim 4 .

10. The method of claim 9 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

11. The method of claim 9 , wherein the pharmaceutically acceptable salt is a bis(hydrochloride) salt.

12. The method of claim 9 , wherein the pharmaceutical composition is formulated for parenteral administration.

13. The method of claim 9 , wherein the pharmaceutical composition is formulated for oral administration.

14. The method of claim 9 , wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

15. The method of claim 9 , wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

16. The method of claim 9 , wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

Assignees

• Biocryst Pharm Inc

Inventors

• Kotian Pravin L
• Babu Yarlagadda S
• Wu Minwan
• Chintareddy Venkat R
• Kumar V Satish
• Zhang Weihe

Classifications

• C07D231/14 Primary

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title